Overview Dividends

(ARE) Alexandria Real Estate - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0152711091

Laboratories, Offices, Campuses, Venture Capital

ARE EPS (Earnings per Share)

EPS (Earnings per Share) of ARE over the last years for every Quarter: "2020-09": 0.56, "2020-12": 0.62, "2021-03": 0.72, "2021-06": 0.73, "2021-09": 0.7, "2021-12": 0.58, "2022-03": 0.71, "2022-06": 0.78, "2022-09": 0.35, "2022-12": 0.31, "2023-03": 0.83, "2023-06": 0.51, "2023-09": 0.87, "2023-12": 0.82, "2024-03": 0.89, "2024-06": 0.88, "2024-09": 0.87, "2024-12": 0.69, "2025-03": 0.51, "2025-06": 0.48, "2025-09": 0.5,
EPS Growth (3Y CAGR): 18.99%
EPS Trend (3Y Correlation): -2.4%

ARE Revenue

Revenue of ARE over the last years for every Quarter: 2020-09: 545.042, 2020-12: 463.72, 2021-03: 479.849, 2021-06: 509.619, 2021-09: 547.759, 2021-12: 576.923, 2022-03: 615.065, 2022-06: 643.764, 2022-09: 659.852, 2022-12: 670.281, 2023-03: 687.949, 2023-06: 704.339, 2023-09: 707.531, 2023-12: 742.637, 2024-03: 755.551, 2024-06: 755.162, 2024-09: 775.744, 2024-12: 763.249, 2025-03: 743.175, 2025-06: 762.04, 2025-09: 751.944,
Revenue Growth (3Y CAGR): 4.27%
Revenue Trend (3Y Correlation): 82.9%
Risk via 10d forecast
Volatility 36.5%
Value at Risk 5%th 56.6%
Relative Tail Risk -5.72%
Reward TTM
Sharpe Ratio -1.72
Alpha -60.51
Character TTM
Hurst Exponent 0.438
Beta 0.783
Beta Downside 1.142
Drawdowns 3y
Max DD 64.92%
Mean DD 31.70%
Median DD 29.56%

Description: ARE Alexandria Real Estate October 31, 2025

Alexandria Real Estate Equities (NYSE: ARE) is a S&P 500 life-science REIT that owns, operates, and develops “Megacampus” clusters in premier biotech hubs such as Boston, the Bay Area, San Diego, Seattle, Maryland, the Research Triangle, and New York City. As of 30 June 2025 the company’s market cap is roughly $25.7 billion and it controls about 39.7 million rentable square feet (RSF) of operating space plus an additional 4.4 million RSF of Class A/A+ assets under construction, with one fully pre-leased project slated to break ground within the next year.

Key performance indicators from the most recent quarterly release show an occupancy rate near 96 % and a funds-from-operations (FFO) growth of 7 % year-over-year, driven by strong lease-rate escalations (≈5 % YoY) and a tenant mix weighted toward high-margin biotech and pharma firms. The REIT’s leverage remains moderate at roughly 45 % debt-to-EBITDA, reflecting its disciplined underwriting. Sector-wide, the life-science real-estate market is buoyed by a 12 % annual increase in U.S. biotech venture capital funding and sustained federal R&D spending, which together underpin demand for premium lab and office space.

For a deeper quantitative comparison of Alexandria’s valuation metrics against peers, the ValueRay platform offers a convenient dashboard for further analysis.

ARE Stock Overview

Market Cap in USD 9,611m
Sub-Industry Diversified REITs
IPO / Inception 1997-05-27
Return 12m vs S&P 500 -54.3%
Analyst Rating 3.54 of 5

ARE Dividends

Dividend Yield 10.10%
Yield on Cost 5y 3.89%
Yield CAGR 5y 5.18%
Payout Consistency 96.0%
Payout Ratio 2.4%

ARE Growth Ratios

CAGR 3y -26.36%
CAGR/Max DD Calmar Ratio -0.41
CAGR/Mean DD Pain Ratio -0.83
Current Volume 1422k
Average Volume 2332.4k

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income (-415.7m TTM) > 0 and > 6% of Revenue (6% = 181.2m TTM)
FCFTA 0.04 (>2.0%) and ΔFCFTA 0.39pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 11.55% (prev -55.26%; Δ 66.81pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.04 (>3.0%) and CFO 1.38b > Net Income -415.7m (YES >=105%, WARN >=100%)
Net Debt (13.52b) to EBITDA (1.39b) ratio: 9.70 <= 3.0 (WARN <= 3.5)
Current Ratio 2.51 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (170.1m) change vs 12m ago -1.12% (target <= -2.0% for YES)
Gross Margin 69.19% (prev 70.57%; Δ -1.37pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 7.96% (prev 7.87%; Δ 0.09pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 0.21 (EBITDA TTM 1.39b / Interest Expense TTM 161.8m) >= 6 (WARN >= 3)

ValueRay F-Score (Strict, 0-100) 58.69

1. Piotroski 2.50pt = -2.50
2. FCF Yield 5.95% = 2.97
3. FCF Margin 45.55% = 7.50
4. Debt/Equity 0.85 = 2.15
5. Debt/Ebitda 9.70 = -2.50
6. ROIC - WACC (= -3.70)% = -4.63
7. RoE -2.40% = -0.40
8. Rev. Trend 82.85% = 6.21
9. EPS Trend -2.43% = -0.12

What is the price of ARE shares?

As of November 17, 2025, the stock is trading at USD 52.29 with a total of 1,422,029 shares traded.
Over the past week, the price has changed by -3.63%, over one month by -30.49%, over three months by -31.20% and over the past year by -47.16%.

Is Alexandria Real Estate a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Alexandria Real Estate is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 58.69 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ARE is around 42.04 USD . This means that ARE is currently overvalued and has a potential downside of -19.6%.

Is ARE a buy, sell or hold?

Alexandria Real Estate has received a consensus analysts rating of 3.54. Therefor, it is recommend to hold ARE.
  • Strong Buy: 3
  • Buy: 1
  • Hold: 9
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the ARE price?

Issuer Target Up/Down from current
Wallstreet Target Price 77.9 48.9%
Analysts Target Price 77.9 48.9%
ValueRay Target Price 44.9 -14.2%

ARE Fundamental Data Overview November 10, 2025

Market Cap USD = 9.61b (9.61b USD * 1.0 USD.USD)
P/E Forward = 16.6945
P/S = 3.1424
P/B = 0.832
P/EG = 844.2
Beta = 1.324
Revenue TTM = 3.02b USD
EBIT TTM = 34.6m USD
EBITDA TTM = 1.39b USD
Long Term Debt = 12.24b USD (from longTermDebt, last fiscal year)
Short Term Debt = 5.39m USD (from shortTermDebt, last quarter)
Debt = 14.10b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.52b USD (from netDebt column, last quarter)
Enterprise Value = 23.13b USD (9.61b + Debt 14.10b - CCE 579.5m)
Interest Coverage Ratio = 0.21 (Ebit TTM 34.6m / Interest Expense TTM 161.8m)
FCF Yield = 5.95% (FCF TTM 1.38b / Enterprise Value 23.13b)
FCF Margin = 45.55% (FCF TTM 1.38b / Revenue TTM 3.02b)
Net Margin = -13.76% (Net Income TTM -415.7m / Revenue TTM 3.02b)
Gross Margin = 69.19% ((Revenue TTM 3.02b - Cost of Revenue TTM 930.5m) / Revenue TTM)
Gross Margin QoQ = 68.18% (prev 70.55%)
Tobins Q-Ratio = 0.62 (Enterprise Value 23.13b / Total Assets 37.38b)
Interest Expense / Debt = 0.39% (Interest Expense 55.3m / Debt 14.10b)
Taxrate = 21.0% (US default 21%)
NOPAT = 27.3m (EBIT 34.6m * (1 - 21.00%))
Current Ratio = 2.51 (Total Current Assets 579.5m / Total Current Liabilities 230.6m)
Debt / Equity = 0.85 (Debt 14.10b / totalStockholderEquity, last quarter 16.64b)
Debt / EBITDA = 9.70 (Net Debt 13.52b / EBITDA 1.39b)
Debt / FCF = 9.82 (Net Debt 13.52b / FCF TTM 1.38b)
Total Stockholder Equity = 17.29b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.11% (Net Income -415.7m / Total Assets 37.38b)
RoE = -2.40% (Net Income TTM -415.7m / Total Stockholder Equity 17.29b)
RoCE = 0.12% (EBIT 34.6m / Capital Employed (Equity 17.29b + L.T.Debt 12.24b))
RoIC = 0.09% (NOPAT 27.3m / Invested Capital 30.39b)
WACC = 3.79% (E(9.61b)/V(23.71b) * Re(8.90%) + D(14.10b)/V(23.71b) * Rd(0.39%) * (1-Tc(0.21)))
Discount Rate = 8.90% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.28%
[DCF Debug] Terminal Value 66.67% ; FCFE base≈1.33b ; Y1≈874.9m ; Y5≈400.1m
Fair Price DCF = 39.58 (DCF Value 6.84b / Shares Outstanding 172.8m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -2.43 | EPS CAGR: 18.99% | SUE: 0.62 | # QB: 0
Revenue Correlation: 82.85 | Revenue CAGR: 4.27% | SUE: -0.13 | # QB: 0

Additional Sources for ARE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle